Skip to content

Clinical trials

Carcinoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma Clear all

733 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20015
200216
200320
20048
200522
200624
200722
200835
200939
201027
201121
201228
201321
201422
201522
201627
201725
201826
201940
202043
202141
202245
202340
202429
202527
202639

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed345
Recruiting102
Terminated87
Unknown status85
Active, not recruiting48
Withdrawn30
Not yet recruiting25
Enrolling by invitation4
No longer available3
Suspended3
Available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)26
Pfizer21
Novartis Pharmaceuticals19
AstraZeneca17
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13
Amgen10
M.D. Anderson Cancer Center10
Eli Lilly and Company9
Peking University People's Hospital9
H. Lee Moffitt Cancer Center and Research Institute8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma733
Neoplasms215
Carcinoma, Non-Small-Cell Lung133
Neoplasm Metastasis83
Lung Neoplasms75
Adenocarcinoma71
Squamous Cell Carcinoma of Head and Neck63
Neoplasms by Site55
Colorectal Neoplasms46
Carcinoma, Squamous Cell45

Trials

Showing 1 to 25 of 733. Each trial links to its page on Pharma Observatory.

633 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.